ANAVEX LIFE SCIENCES CORP. financial data

Symbol
AVXL on Nasdaq
Location
New York, NY
Fiscal year end
30 September
Latest financial report
10-K - Q3 2025 - 25 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 13% % 36%
Return On Equity -47% % -42%
Return On Assets -41% % -37%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 89,348,107 shares 5.3%
Common Stock, Shares, Outstanding 86,668,521 shares 2.2%
Entity Public Float $708,000,000 USD 72%
Common Stock, Value, Issued $87,000 USD 2.4%
Weighted Average Number of Shares Outstanding, Basic 85,289,447 shares 2.2%
Weighted Average Number of Shares Outstanding, Diluted 85,289,447 shares 2.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $37,592,000 USD -10%
General and Administrative Expense $13,816,000 USD 25%
Operating Income (Loss) $51,408,000 USD 2.8%
Nonoperating Income (Expense) $5,031,000 USD -49%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $43,002,000 USD 9.5%
Net Income (Loss) Attributable to Parent $46,377,000 USD -7.8%
Earnings Per Share, Basic 0 USD/shares -3.8%
Earnings Per Share, Diluted 0 USD/shares -3.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $102,577,000 USD -22%
Assets $103,815,000 USD -23%
Accounts Payable, Current $4,249,000 USD -56%
Accrued Liabilities, Current $3,892,000 USD -20%
Liabilities $8,946,000 USD -42%
Retained Earnings (Accumulated Deficit) $382,448,000 USD -14%
Stockholders' Equity Attributable to Parent $94,869,000 USD -21%
Liabilities and Equity $103,815,000 USD -23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $12,120,000 USD -66%
Net Cash Provided by (Used in) Financing Activities $708,000 USD 1100%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 86,668,521 shares 2.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $102,577,000 USD -22%
Deferred Tax Assets, Valuation Allowance $108,492,000 USD 18%
Deferred Tax Assets, Gross $20,700,000 USD 37%
Deferred Tax Assets, Operating Loss Carryforwards $54,752,000 USD 14%
Current Income Tax Expense (Benefit) $59,000 USD -79%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Share-based Payment Arrangement, Expense $11,500,000 USD 22%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%